表皮性卵巢癌之腹腔內化學治療

Intraperitoneal Chemotherapy for Ovarian Cancer

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 朱益志(Yi-Chih Chu) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2007年2期 (2007/10) Pp. 32-37

https://doi.org/10.7010/JGO.200710.0032

摘要

雖然結合鉑和紫杉醇為主的化學治療，被公認對晚期卵巢癌有效，但是後多數仍有復發的結果，因此，醫界一直在尋求新的藥物和方法來治療，至少期望能求到長期無病灶的生存。
大部份卵巢癌病灶都是經腹腔表面擴散，因此，腹腔內的化學治療是一項合理的想法，在臨床上亦出現持正面效果的研究。其中研究最多的是使用以鉑為主之化療，顯示比靜脈注射為佳，但迄今為止尚因副作用和導管使用難題，未被普遍接受。未來，以carboplatin和topotecan做腹腔內化學治療之方法，是否能更被接受，尚待研究。

關鍵字

化學治療 ； 腹腔內 ； 卵巢癌

並列摘要

Despite the high objective response rate of patients with advanced epithelial ovarian cancer to combination cisplatin and paclitaxel-based chemotherapy, the majority of individuals ultimately develop disease recurrence. Thus, new agents or treatment strategies are required to substantially improve the long-term disease-free survival potential in this malignancy.
One of the most characteristic features of ovarian cancer is the intraperitoneal distribution of disease that commonly accompanies the diagnosis. Therefore, intraperitoneal (IP) chemotherapy is a reasonable approach in the treatment for ovarian cancer, and it has been extensively investigated both pre-clinically and clinically. There are several studies comparing intraperitoneal versus intravenous cisplatin-based chemotherapy. Although all of the trials have shown survival benefit of intraperitoneal chemotherapy, this approach has not been accepted as a standard treatment for select ovarian cancer patients. Intraperitoneal carboplatin & topotecan should be considered as high priority in the future studies.

並列關鍵字

Chemotherapy ； Intraperitoneal ； Ovarian cancer